Immunome IMNM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $582.69M+126% | $653.48M+356% | $272.64M+75.3% | $143.88M-13.0% | $257.61M-4.5% | ||
| $210K+110% | $210K+110% | $210K+110% | $210K+110% | $100K0.0% | ||
| $35.59M+80.8% | $29.78M+70.2% | $26.52M+32.5% | $23.15M+37.1% | $19.68M+63.2% | ||
| $594.31M+83.9% | $660.78M+199% | $279.92M+14.7% | $277.43M-2.4% | $323.13M+3.1% | ||
| $17.08M+55.9% | $14.64M+44.7% | $11.56M+61.2% | $11.03M+80.9% | $10.95M+155% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M— | $4.35M— | ||
| $619.79M+80.9% | $683.19M+184% | $299.38M+16.5% | $296.29M0.0% | $342.69M+7.2% | ||
| $19.68M-41.9% | $23.27M-27.1% | $34.12M+62.1% | $31.49M+55.0% | $33.88M+99.6% | ||
| $21.88M+23.9% | $41.65M+25.5% | $25.3M-3.9% | $18.22M-10.1% | $17.66M+62.8% | ||
| —— | $0-100% | $0-100% | $0-100% | $4.02M-68.5% | ||
| $27.41M-11.0% | $44.99M-17.2% | $31.45M-20.4% | $22.88M-42.7% | $30.8M+0.1% | ||
| $3.69M-22.6% | $3.86M-19.2% | $4.01M+62.9% | $4.14M— | $4.77M— | ||
| $3.69M-22.6% | $3.86M— | $4.01M— | $4.14M— | $4.77M— | ||
| $31.11M-12.5% | $48.85M-17.3% | $35.46M-15.6% | $27.02M-36.2% | $35.57M+4.1% | ||
| $11K+22.2% | $11K+83.3% | $9K+50.0% | $9K+50.0% | $9K+50.0% | ||
| $1.37B+58.5% | $1.36B+95.5% | $922.17M+41.8% | $870.09M+35.5% | $864.53M+35.5% | ||
| -$782M-40.3% | -$728.16M-41.2% | -$658.26M-51.1% | -$600.81M-54.7% | -$557.41M-58.2% | ||
| —— | $0-100% | $0-100% | -$24K— | -$3K— | ||
| $588.69M+91.7% | $634.34M+250% | $263.92M+22.8% | $269.27M+6.1% | $307.13M+7.5% | ||
| $619.79M+80.9% | $683.19M+184% | $299.38M+16.5% | $296.29M0.0% | $342.69M+7.2% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M— | $4.35M— | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M— | $4.35M— | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M— | $4.35M— | ||
| $21.88M+23.9% | $41.65M+25.5% | $25.3M-3.9% | $18.22M-10.1% | $17.66M+62.8% | ||
| $3.69M-22.6% | $3.86M-20.2% | $4.01M+47.5% | $4.14M— | $4.77M— | ||
| $11K+22.2% | $11K+83.3% | $9K+50.0% | $9K+50.0% | $9K+50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Immunome cover its short-term obligations?
- Its current ratio is 21.68 — current assets exceed current liabilities.
- Where does Immunome's balance sheet data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.